CN112384214A - 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑 - Google Patents

作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑 Download PDF

Info

Publication number
CN112384214A
CN112384214A CN201980045881.XA CN201980045881A CN112384214A CN 112384214 A CN112384214 A CN 112384214A CN 201980045881 A CN201980045881 A CN 201980045881A CN 112384214 A CN112384214 A CN 112384214A
Authority
CN
China
Prior art keywords
alkyl
heterocyclyl
compound
optionally
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980045881.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·胡贝尔
J·M·厄尔特
R·施特赖歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN112384214A publication Critical patent/CN112384214A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980045881.XA 2018-07-12 2019-07-09 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑 Pending CN112384214A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696887P 2018-07-12 2018-07-12
US62/696,887 2018-07-12
PCT/EP2019/068448 WO2020011804A1 (en) 2018-07-12 2019-07-09 Alkoxy pyrazoles as soluble guanylate cyclase activators

Publications (1)

Publication Number Publication Date
CN112384214A true CN112384214A (zh) 2021-02-19

Family

ID=67314737

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045881.XA Pending CN112384214A (zh) 2018-07-12 2019-07-09 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑

Country Status (14)

Country Link
US (1) US11690848B2 (https=)
EP (1) EP3820470B1 (https=)
JP (2) JP2021530488A (https=)
KR (1) KR20210032443A (https=)
CN (1) CN112384214A (https=)
AU (1) AU2019301887A1 (https=)
BR (1) BR112020025670A2 (https=)
CA (1) CA3103727A1 (https=)
CL (1) CL2021000023A1 (https=)
EA (1) EA202190193A1 (https=)
MA (1) MA53118A (https=)
MX (1) MX2021000405A (https=)
PH (1) PH12021550075A1 (https=)
WO (1) WO2020011804A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118900690A (zh) * 2022-03-21 2024-11-05 勃林格殷格翰国际有限公司 用于治疗门脉高压的可溶性鸟苷酸环化酶活化剂
WO2024097316A1 (en) 2022-11-04 2024-05-10 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating systemic sclerosis
US20240199590A1 (en) 2022-12-09 2024-06-20 Boehringer Ingelheim International Gmbh Solid forms of a sgc activator
WO2025036839A1 (en) * 2023-08-16 2025-02-20 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619695A (zh) * 2012-09-07 2015-05-13 勃林格殷格翰国际有限公司 作为可溶性鸟苷酸环化酶活化剂的烷氧吡唑
WO2017136309A1 (en) * 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10925876B2 (en) 2016-05-18 2021-02-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619695A (zh) * 2012-09-07 2015-05-13 勃林格殷格翰国际有限公司 作为可溶性鸟苷酸环化酶活化剂的烷氧吡唑
WO2017136309A1 (en) * 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

Also Published As

Publication number Publication date
MX2021000405A (es) 2021-03-25
CA3103727A1 (en) 2020-01-16
MA53118A (fr) 2021-05-19
KR20210032443A (ko) 2021-03-24
WO2020011804A1 (en) 2020-01-16
EA202190193A1 (ru) 2021-06-16
AU2019301887A1 (en) 2021-01-07
JP2021530488A (ja) 2021-11-11
JP2024095711A (ja) 2024-07-10
US20210121473A1 (en) 2021-04-29
US11690848B2 (en) 2023-07-04
BR112020025670A2 (pt) 2021-03-16
CL2021000023A1 (es) 2021-06-11
PH12021550075A1 (en) 2021-09-20
EP3820470A1 (en) 2021-05-19
EP3820470B1 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
TWI852999B (zh) 治療脂肪性肝病及/或脂肪性肝炎的方法
JP6180420B2 (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
HUP0301336A2 (hu) Réztartalmú amin-oxidázok inhibitorai és alkalmazásuk gyógyszerkészítmények előállítására
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
CA3037146A1 (en) Method of reducing thyroid-associated side effects
KR20110093841A (ko) 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법
CN102655866B (zh) 糖尿病的治疗或预防药
TWI867086B (zh) 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法
JP5786714B2 (ja) 神経障害性疼痛の治療剤又は予防剤
US20120213867A1 (en) Raf inhibitors for the treatment of thyroid cancer
CN118900690A (zh) 用于治疗门脉高压的可溶性鸟苷酸环化酶活化剂
EA042973B1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
US20060084612A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
JP5559696B2 (ja) 糖尿病性腎症の治療剤
WO2025207099A1 (en) Ppar-delta inhibitors for preventing post-operative atrial fibrillation
WO2025101652A1 (en) Selective mammalian sterile 20-like kinase 1 (mst1) modulator compounds as therapeutics for diabetes and liver regeneration
JP2667495B2 (ja) 脳機能改善剤
JP6851826B2 (ja) がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
HK40054971A (en) Method for treating fatty liver disease and/or steatohepatitis
WO2018012634A1 (ja) 不飽和複素５員環含有化合物を含有する肺高血圧症の予防又は治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210219

WD01 Invention patent application deemed withdrawn after publication